foxo4-dri peptide senolytic skin FOXO4-DRI: Human Trial Status, Cancer Research & Data Frontiers | Senolytic Peptide FOXO4-DRI

BPC 157, or Body Protective Compound 157, is a peptide derived from a naturally occurring protein in the human body

Primary endpoints should center on pain and function Knee Injury and Osteoarthritis Outcome Score (KOOS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Patient-Reported Outcome Measurement Information System (PROMIS) scores), structure (MRI evaluation with delayed gadolinium-enhanced MRI of cartilage (dGEMRIC) when appropriate), and time to milestones (return to sport)

Join now at www.consumerlab.com/join/ Join over 300,000 people on our weekly email list

If injecting BPC-157 first, wait until the peptide absorbs before applying cold (about 45-60 minutes)